HeimVCEL • NASDAQ
Vericel Corp
43,68 $
27. sep., 13:20:28 GMT-4 · USD · NASDAQ · Lagalegir fyrirvarar
HlutabréfSkráð hlutabréf í BandaríkinHöfuðstöðvar: Bandaríkin
Við síðustu lokun
44,07 $
Dagbil
43,68 $ - 44,61 $
Árabil
30,18 $ - 54,09 $
Markaðsvirði
2,14 ma. USD
Meðalmagn
338,85 þ.
V/H-hlutf.
2.309,89
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(USD)jún. 2024Breyting á/á
Tekjur
52,66 m.14,68%
Rekstrarkostnaður
42,63 m.18,75%
Nettótekjur
-4,68 m.6,73%
Hagnaðarhlutfall
-8,8918,66%
Hagnaður á hvern hlut
-0,109,09%
EBITDA
-4,71 m.1,71%
Virkt skatthlutfall
Heildareignir
Heildarskuldir
(USD)jún. 2024Breyting á/á
Reiðufé og skammtímafjárfestingar
102,51 m.4,78%
Heildareignir
376,84 m.21,28%
Heildarskuldir
133,86 m.19,75%
Eigið fé alls
242,98 m.
Útistandandi hlutabréf
49,03 m.
Eiginfjárgengi
8,87
Arðsemi eigna
-4,11%
Ávöxtun eigin fjár
-4,54%
Breyting á handbæru fé
(USD)jún. 2024Breyting á/á
Nettótekjur
-4,68 m.6,73%
Handbært fé frá rekstri
18,54 m.81,79%
Reiðufé frá fjárfestingum
-17,72 m.-635,84%
Reiðufé frá fjármögnun
4,30 m.259,50%
Breyting á handbæru fé
5,11 m.-43,09%
Frjálst peningaflæði
-16,22 m.15,78%
Um
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan. In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before. In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts. Wikipedia
Framkvæmdastjóri
Stofnsett
1989
Vefsvæði
Starfsfólk
314
Leit
Hreinsa leit
Loka leit
Google forrit
Aðalvalmynd